Informationen:
Fehler:
ID
22263
Beschreibung
Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00585416
Link
https://clinicaltrials.gov/show/NCT00585416
Stichworte
Versionen (1)
- 27.05.17 27.05.17 -
Hochgeladen am
27. Mai 2017
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Prostate Cancer NCT00585416
Eligibility Prostate Cancer NCT00585416
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Prostate Cancer NCT00585416
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
metastatic hormone refractory prostate cancer
Item
metastatic hormone refractory prostate cancer.
boolean
C0936223 (UMLS CUI [1,1])
C1328504 (UMLS CUI [1,2])
C1328504 (UMLS CUI [1,2])
ecog
Item
eastern cooperative oncology group (ecog) performance status of 0-1.
boolean
C1520224 (UMLS CUI [1])
testosterone, androgen deprivation
Item
testosterone <50ng/dl. patients must continue primary androgen deprivation with an lhrh analogue if they have not undergone orchiectomy.
boolean
C0039601 (UMLS CUI [1])
C0279492 (UMLS CUI [2])
C0279492 (UMLS CUI [2])
disease progression after androgen deprivation
Item
progressive disease after androgen deprivation.
boolean
C1328504 (UMLS CUI [1])
chemotherapy indicated by patient condition
Item
patients whose clinical condition would make chemotherapy clearly indicated.
boolean
C0392920 (UMLS CUI [1,1])
C1444656 (UMLS CUI [1,2])
C0683521 (UMLS CUI [1,3])
C1444656 (UMLS CUI [1,2])
C0683521 (UMLS CUI [1,3])
systemic chemotherapy for metastatic disease
Item
patients who have received systemic chemotherapy for the treatment of metastatic disease.
boolean
C1883256 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
C0027627 (UMLS CUI [1,2])
peripheral neuropathy
Item
peripheral neuropathy > grade 1
boolean
C0031117 (UMLS CUI [1])
anti-angiogenic therapy
Item
prior anti-angiogenic therapy, including thalidomide.
boolean
C0596087 (UMLS CUI [1])
surgery recovery, prior major surgery or radiation
Item
patients with inadequate recovery from any prior surgical procedure, or patients having undergone any major surgical procedure or radiation within 4 weeks prior to study entry.
boolean
C0543467 (UMLS CUI [1,1])
C2004454 (UMLS CUI [1,2])
C0679637 (UMLS CUI [2])
C1522449 (UMLS CUI [3])
C2004454 (UMLS CUI [1,2])
C0679637 (UMLS CUI [2])
C1522449 (UMLS CUI [3])
radiopharmaceuticals
Item
patients who have received radiopharmaceuticals (strontium, samarium) within 8 weeks prior to enrollment.
boolean
C0182638 (UMLS CUI [1])
brain metastasis
Item
patients with known brain metastases or history of brain metastases.
boolean
C0220650 (UMLS CUI [1])
surgery recovery, neurological limitations
Item
history of stroke within 6 months of treatment or other significant neurological limitations.
boolean
C0038454 (UMLS CUI [1])
C0027765 (UMLS CUI [2])
C0027765 (UMLS CUI [2])
investigational treatment
Item
patients who have received more than 2 prior investigational treatments.
boolean
C0949266 (UMLS CUI [1])
comorbidities
Item
uncontrolled intercurrent illness
boolean
C0009488 (UMLS CUI [1])
myocardial infarction, hospitalizations for congestive heart failure, cardiac arrhythmias
Item
patients with a history of a myocardial infarction within the prior 6 months or, hospitalizations for decompensated congestive heart failure within the prior 6 months, or history of significant / symptomatic cardiac arrhythmias
boolean
C0027051 (UMLS CUI [1])
C0018802 (UMLS CUI [2,1])
C0019993 (UMLS CUI [2,2])
C0003811 (UMLS CUI [3])
C0018802 (UMLS CUI [2,1])
C0019993 (UMLS CUI [2,2])
C0003811 (UMLS CUI [3])